Financial Performance - The company's revenue for Q1 2025 was ¥4,389,897,045, a decrease of 29.42% compared to ¥6,219,417,413 in the same period last year[5] - Net profit attributable to shareholders was ¥584,242,512, down 43.07% from ¥1,026,188,176 year-on-year[5] - Basic and diluted earnings per share were both ¥0.37, reflecting a decline of 44.78% from ¥0.67 in the same period last year[5] - Total operating revenue decreased to ¥4,389,897,045, down 29.5% from ¥6,219,417,413 in the previous period[24] - Net profit for the period was ¥659,587,476, representing a 48.7% decrease from ¥1,285,801,413 in the prior year[25] - The total comprehensive income for the period was CNY 653,323,410, a decrease from CNY 1,284,956,201 in the previous period[26] Cash Flow - The net cash flow from operating activities decreased by 64.86%, amounting to ¥449,384,244 compared to ¥1,278,763,116 in the previous year[10] - Net cash flow from operating activities was CNY 449,384,244, significantly lower than CNY 1,278,763,116 in the previous period[28] - Cash inflow from operating activities totaled CNY 5,184,117,253, compared to CNY 6,561,069,026 in the previous period[27] - Cash outflow from operating activities was CNY 4,734,733,009, down from CNY 5,282,305,910 in the previous period[27] - Net cash flow from investing activities was negative CNY 690,071,360, a decline from positive CNY 670,633,809 in the previous period[28] - Cash inflow from investing activities was CNY 4,018,350,908, compared to CNY 1,772,849,022 in the previous period[28] - Cash outflow from financing activities was CNY 1,063,394,172, down from CNY 1,512,332,605 in the previous period[28] - The ending balance of cash and cash equivalents was CNY 4,075,118,403, down from CNY 6,231,493,756 in the previous period[28] Assets and Liabilities - Total assets increased by 1.37% to ¥37,826,228,881 from ¥37,316,259,482 at the end of the previous year[5] - Current liabilities totaled ¥9,092,533,232, slightly down from ¥9,137,877,768, a decrease of 0.5%[23] - Long-term borrowings decreased to ¥196,000,000 from ¥342,000,000, a reduction of 42.8%[23] - The company's equity attributable to shareholders increased to ¥23,094,459,078, up from ¥22,479,520,446, a rise of 2.7%[23] Investment and Income - Investment income decreased by 45.17%, amounting to ¥61,314,415 compared to ¥111,835,302 in the previous year[9] - The company reported an increase in investment income to ¥61,314,415 from ¥111,835,302, a decline of 45%[25] - The company reported a total investment of 10,000 million in structured deposits with a floating return of 2.50%[15] Shareholder Information - The total number of common shareholders at the end of the reporting period is 33,389[11] - Liu Gexin holds 23.72% of the shares, totaling 379,128,280 shares, with 284,346,210 shares under lock-up and 106,014,000 shares pledged[11] - The second largest shareholder, Yaan State-owned Assets Management Co., Ltd., holds 6.07% of the shares, totaling 96,983,174 shares, with 34,010,800 shares pledged[11] - The top 10 shareholders collectively hold significant stakes, with the largest shareholder holding nearly 24%[11] - The company has no preferred shareholders as of the reporting period[12] Research and Development - The company has received approval for its subsidiary's PD-L1 antibody, indicating progress in its product pipeline[18] - A new drug application for the core product, Boduqumab, has been accepted by the National Medical Products Administration, highlighting ongoing R&D efforts[18] - The company has established an exclusive licensing agreement for SKB378/HBM9378, which may enhance its market position[18] Financial Management - The company did not engage in any significant financial management activities during the reporting period[12] - The company plans to continue its financial management strategy, including potential future entrusted wealth management plans[21] Miscellaneous - The company reported a total of 424,982,000.00 in financial assets, with a significant increase in cash and cash equivalents to 4,092,787,913.00 from 3,973,908,715.00[21] - The trading financial assets rose to 2,231,249,987.00, up from 1,921,163,411.00, indicating a growth of approximately 16.2%[21] - Accounts receivable decreased slightly to 4,726,326,218.00 from 4,795,035,595.00, reflecting a reduction of about 1.4%[21] - Inventory levels increased to 3,827,874,323.00 from 3,800,617,271.00, showing a growth of approximately 0.7%[21] - The company completed the cancellation of repurchased shares, indicating a strategic move to enhance shareholder value[19] - The company's first quarter report was not audited[29]

Financial Performance - The company's operating revenue for Q1 2025 was ¥691,048,480.64, a decrease of 9.59% compared to ¥764,358,427.34 in the same period last year[4]. - The net profit attributable to shareholders was -¥93,385,351.77, compared to -¥70,990,258.37 in the previous year, indicating a worsening performance[4]. - The basic and diluted earnings per share were both -¥0.17, compared to -¥0.13 in the same period last year[4]. - The company reported a net loss of RMB 223,794,180.34 for the period, compared to a loss of RMB 130,408,828.57 in the previous period, indicating a worsening of approximately 71.5%[14]. - The total comprehensive loss for Q1 2025 was ¥94,290,823.33, compared to a loss of ¥72,889,279.98 in Q1 2024, reflecting a worsening financial position[18]. Cash Flow and Liquidity - The net cash flow from operating activities was -¥23,470,983.11, an improvement from -¥37,158,495.23 in the previous year[4]. - Cash flow from operating activities for Q1 2025 was a net outflow of ¥23,470,983.11, an improvement from a net outflow of ¥37,158,495.23 in Q1 2024[22]. - The company raised ¥322,500,000.00 in borrowings during Q1 2025, compared to ¥170,000,000.00 in Q1 2024, indicating a significant increase in financing activities[23]. - Cash and cash equivalents at the end of Q1 2025 totaled ¥331,787,417.40, down from ¥355,639,074.08 at the end of Q1 2024[23]. - The company's cash and cash equivalents were RMB 370,005,584.32, down from RMB 385,710,196.80, indicating a decrease of about 8.8%[12]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,419,031,812.05, a decrease of 2.44% from ¥5,554,807,122.62 at the end of the previous year[5]. - As of March 31, 2025, the total assets amounted to RMB 5,419,031,812.05, a decrease from RMB 5,554,807,122.62 as of December 31, 2024, reflecting a decline of approximately 2.43%[12][15]. - The total liabilities were RMB 3,258,866,282.14, down from RMB 3,300,350,769.38, indicating a decrease of approximately 1.3%[14]. - Current liabilities totaled RMB 2,621,537,310.09, a slight decrease from RMB 2,675,249,640.80, reflecting a decline of about 2.0%[14]. - The equity attributable to shareholders decreased by 4.18% to ¥2,160,165,529.91 from ¥2,254,456,353.24 at the end of the previous year[5]. Operational Metrics - The company reported a decrease in new product technology development revenue and a decline in gross margin for structural components[7]. - Research and development expenses increased to ¥50,169,873.00 in Q1 2025, up 10.5% from ¥45,385,868.24 in Q1 2024[17]. - Total operating costs for Q1 2025 were ¥792,871,293.85, down 6.2% from ¥845,298,269.26 in Q1 2024[17]. - The weighted average return on net assets was -4.23%, compared to -2.55% in the previous year[5]. - The company expects an increase in sales in the second half of 2024, which may improve cash flow from operating activities[7]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 83,286[8]. - The company has not reported any significant changes in major shareholders or their shareholdings during the reporting period[11]. - There are no new strategies or product developments mentioned in the current report[11].

Financial Performance - The company's operating revenue for 2024 reached RMB 714,369,070.89, representing a 6.36% increase compared to RMB 671,626,943.73 in 2023[24]. - Net profit attributable to shareholders for 2024 was RMB 200,700,773.72, a 23.21% increase from RMB 162,896,651.50 in 2023[24]. - The net cash flow from operating activities for 2024 was RMB 205,715,849.04, reflecting a 5.61% increase from RMB 194,780,877.43 in 2023[24]. - Total assets at the end of 2024 were RMB 1,728,380,749.86, a decrease of 8.68% from RMB 1,892,765,912.73 at the end of 2023[25]. - The net assets attributable to shareholders increased to RMB 1,260,084,487.42, up 5.68% from RMB 1,192,314,263.44 at the end of 2023[25]. - Basic earnings per share increased by 22.00% to CNY 0.61 compared to CNY 0.50 in 2023[26]. - The company reported a decrease of 18.06% in net profit attributable to shareholders after deducting non-recurring gains and losses, amounting to RMB 126,863,340.37 in 2024[24]. - Net profit attributable to shareholders rose by 6.36% due to increased operating revenue and asset disposal gains from Jiangsu Chengyi[27]. - Net profit excluding non-recurring gains decreased by 17.02% to CNY 0.39 per share, attributed to declining investment income and increased losses from subsidiary San Da Yuan[26][27]. Cash Flow and Investments - The company reported a net cash flow from operating activities of CNY 205,685,928.34 for the year, with a notable increase in Q4 to CNY 100,731,581.70[29]. - The net cash flow from investing activities improved significantly to CNY 26,181,722.11, compared to a negative cash flow of CNY -59,600,658.72 in the previous year, primarily from the sale of fixed assets by a subsidiary[54]. - The company experienced a 55.92% increase in taxes and surcharges, totaling CNY 14,329,993.19, due to higher property and value-added taxes[54]. Market and Product Development - The main product, glucosamine hydrochloride capsules, secured over 41% market share in 9 provinces after winning the national procurement bid in August 2020, with the procurement period ending in October 2023[42]. - The company is actively communicating with provincial institutions for contract renewals to maintain market share and has expanded sales through national procurement across 30 provinces[42]. - New product developments include the successful approval of bone calcitriol soft capsules and levocarnitine injection, with ongoing consistency evaluations for lidocaine injection and amikacin sulfate injection[40]. - The company plans to enhance product research and development, focusing on anti-tumor and liver protection drugs to diversify its product line[48]. - The company has established long-term stable partnerships with well-known pharmaceutical companies, facilitating further cooperation in raw material production[48]. - The company is focusing on high-end small varieties of "marine drugs" and "major disease medications" to drive future growth[103]. Research and Development - The company has over 30 products in development, focusing on marine drugs, geriatric medications, and anti-tumor drugs[88]. - The company holds 21 valid authorized invention patents, with 5 products recognized as "Excellent Industrial Products" in Zhejiang Province[88]. - The company has initiated consistency evaluation for 9 oral solid preparations, with one key product approved[89]. - The company plans to increase investment in drug research and development and strengthen cooperation with research institutions[90]. - The company reported a research and development (R&D) investment of 6.59% of operating revenue, which is lower than the industry average of 7.14%[98]. Governance and Compliance - The company has established a governance structure that complies with relevant laws and regulations, ensuring the protection of shareholder rights and interests[123]. - There are no reported instances of the controlling shareholder interfering with the company's decision-making processes, maintaining operational independence[124]. - The company has implemented strict information disclosure practices to enhance transparency and prevent insider trading, thereby protecting shareholder rights[126]. - The company is committed to improving its governance structure and internal control mechanisms to ensure sustainable development[126]. - The company has not faced any regulatory requirements for rectification regarding its governance practices[126]. Environmental Responsibility - The company has not experienced any environmental pollution incidents or exceeded discharge limits during the reporting period[167]. - The company has established a comprehensive emergency response plan for environmental incidents, which was approved by the local environmental bureau in December 2024[185]. - The company has implemented carbon reduction measures, successfully reducing CO2 equivalent emissions by 537 tons[188]. - The company has committed to avoiding any competitive actions that could harm the interests of Kang Le Pharmaceutical, ensuring compliance with all relevant regulations[190]. Employee and Management Structure - The total employee compensation for the company reached 99,356,459, with an average of 1,124.33 per employee[130]. - The company has a strong leadership team with extensive experience in the pharmaceutical industry, including positions in various pharmaceutical companies and associations[131]. - The company has a diverse board of directors with expertise in finance, law, and pharmaceuticals, which supports its strategic decision-making[132]. - The performance evaluation mechanism for senior management includes a salary structure of "annual salary + annual performance bonus," with 30% of the salary reserved and linked to sales and net profit targets[162].

云南罗平锌电股份有限公司 2025 年第一季度报告 证券代码：002114 证券简称：罗平锌电 公告编号：2025-017 云南罗平锌电股份有限公司 2025 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 公司是否需追溯调整或重述以前年度会计数据 □是 否 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经审计 □是 否 1 云南罗平锌电股份有限公司 2025 年第一季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 | | 本报告期 | 上年同期 | 本报告期比上年同期增减（%） | | --- | --- | --- | --- | | 营业收入（元） | 185,136,761.18 | 398,567,867.77 | -53.55% | | 归属于上市公司股东的净利 | -45, ...

Financial Performance - The company's revenue for Q1 2025 was ¥487,938,576.38, a decrease of 1.43% compared to ¥495,015,341.33 in the same period last year[4] - The net profit attributable to shareholders was a loss of ¥24,081,717.75, an improvement of 2.48% from a loss of ¥24,694,790.16 in the previous year[4] - Operating profit for the current period is -¥22,088,244.85, an improvement from -¥25,455,193.69 in the previous period[16] - The total comprehensive income attributable to the parent company was -24,081,717.75 yuan, compared to -24,694,790.16 yuan in the previous period[17] - The company reported a basic and diluted earnings per share of -0.03 yuan, consistent with the previous period[17] Cash Flow - The net cash flow from operating activities improved significantly, with a net outflow of ¥52,302,347.66, representing a 58.16% increase compared to a net outflow of ¥125,018,195.82 last year[4] - Cash inflow from operating activities totaled 495,219,962.67 yuan, up from 367,344,346.29 yuan year-over-year[18] - Cash outflow from operating activities increased to 547,522,310.33 yuan, compared to 492,362,542.11 yuan in the previous period[18] - The net cash flow from investing activities was -99,795,771.45 yuan, an improvement from -142,698,075.81 yuan in the previous period[18] - Cash inflow from financing activities was 65,354,777.14 yuan, compared to 46,907,166.13 yuan in the previous period[18] - The net cash flow from financing activities was 31,615,101.78 yuan, down from 44,787,100.27 yuan in the previous period[18] - The ending cash and cash equivalents balance was 218,278,240.16 yuan, down from 298,133,718.30 yuan in the previous period[18] - The company received tax refunds amounting to 50,126,456.34 yuan, compared to 13,550,822.58 yuan in the previous period[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,307,004,879.51, a decrease of 0.71% from ¥4,337,700,017.96 at the end of the previous year[4] - Total current assets decreased to ¥1,347,851,267.22 from ¥1,400,582,531.62, a decline of 3.8%[14] - Total non-current assets increased to ¥2,959,153,612.29 from ¥2,937,117,486.34, a rise of 0.7%[14] - Total liabilities decreased to ¥1,539,692,092.41 from ¥1,546,305,513.11, a reduction of 0.4%[14] - Total equity attributable to shareholders decreased to ¥2,767,312,787.10 from ¥2,791,394,504.85, a decline of 0.9%[14] Shareholder Information - The total number of common shareholders at the end of the reporting period is 56,025, with no preferred shareholders having restored voting rights[8] - The largest shareholder, Hefei Industrial Investment Holding (Group) Co., Ltd., holds 260,841,634 shares, representing 29.11% of total shares[8] Investment Activities - The company plans to terminate its remaining contributions to two investment funds, as approved by the board and shareholders[10] - The company intends to transfer assets of its polyimide subsidiary to Hefei Guofeng Advanced Materials Technology Co., Ltd. at book value[10] - The company is set to acquire 46,263,796 shares of Taihu Jinzhang Technology Co., Ltd., which will represent 58.33% of the total share capital post-cancellation of treasury shares[10] Other Financial Metrics - The company reported a significant increase in fair value changes, with a gain of ¥562,022.30, up 691.97% from a loss of ¥94,940.79 in the previous year[7] - The company experienced an 84.64% increase in receivables financing, rising to ¥56,866,050.58 from ¥30,798,423.13 year-over-year[7] - The company recorded a 485.59% increase in asset disposal gains, amounting to ¥1,163,932.45 compared to ¥198,761.26 in the previous year[7] - The company’s investment income decreased by 30.61% to ¥1,958,750.01 from ¥2,822,798.54 year-over-year[7] - The company reported a 170.14% increase in other operating income, totaling ¥620,900.56 compared to ¥229,844.10 in the previous year[7] - Total operating costs for the current period amount to ¥518,253,628.18, down 1.4% from ¥526,159,170.94 in the previous period[16] - Inventory increased to ¥267,681,938.80 from ¥228,098,928.86, an increase of 17.3%[14] - Short-term borrowings increased to ¥147,356,456.41 from ¥145,020,412.93, a rise of 1.6%[14]

Financial Performance - The company's revenue for Q1 2025 was ¥2,132,933,173.91, representing a 6.55% increase compared to ¥2,001,806,934.69 in the same period last year[4]. - Net profit attributable to shareholders decreased by 28.46% to ¥75,258,380.02 from ¥105,202,043.73 year-on-year[4]. - The company reported a 33.07% decrease in net profit attributable to shareholders after deducting non-recurring gains and losses, amounting to ¥59,312,105.67 compared to ¥88,615,262.71 in the previous year[9]. - Net profit for the current period was ¥93,347,070.01, a decrease of 27.73% from ¥129,260,200.91 in the previous period[19]. - Earnings per share (EPS) decreased to ¥0.0965 from ¥0.1349 in the previous period, reflecting a decline of 28.38%[20]. Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥524,656,260.47, a significant decline of 1,010.37% compared to -¥47,250,462.82 in the previous year[4]. - Cash inflow from operating activities totaled ¥2,933,828,098.13, down from ¥3,051,691,287.04 in the previous period[21]. - Total cash outflow from operating activities amounted to 3,458,484,358.60, up from 3,098,941,749.86, reflecting an increase of approximately 11.6%[22]. - The ending balance of cash and cash equivalents was 714,013,235.70, down from 1,595,787,035.64, reflecting a decrease of about 55.3%[22]. - Cash paid to employees was 216,384,229.77, an increase from 201,832,253.34, indicating a rise of approximately 7.8%[22]. - Cash paid for taxes was 146,092,454.08, down from 172,926,995.05, showing a decrease of about 15.5%[22]. - Cash paid for other operating activities was 172,903,585.59, slightly up from 163,283,255.13, reflecting an increase of about 5.0%[22]. Assets and Liabilities - The total assets at the end of the reporting period were ¥12,537,314,854.17, down 5.10% from ¥13,211,334,136.52 at the end of the previous year[4]. - Total liabilities decreased to ¥6,695,463,105.77 from ¥7,465,531,509.51, a reduction of 10.31%[17]. - Current liabilities decreased from ¥6,033,082,258.21 to ¥5,133,611,636.30, a reduction of approximately 14.9%[16]. - Total equity increased to ¥5,841,851,748.40 from ¥5,745,802,627.01, an increase of 1.67%[17]. Operational Efficiency - The company experienced a significant reduction in gross profit due to pressure on the department store and supermarket sectors, which affected overall profitability[5]. - The increase in accounts receivable was 38.54%, rising to ¥274,971,970.25 from ¥198,482,632.53, primarily due to an increase in customer payments and goods receivable[8]. - Long-term borrowings increased by 34.35% to ¥586,836,448.84 from ¥436,780,980.63, mainly due to loans for the construction of the Feixi Logistics Park project[8]. - Inventory decreased from ¥2,594,730,926.19 to ¥2,453,037,316.43, a reduction of approximately 5.5%[15]. - The company reported a significant increase in accounts payable, which rose from ¥1,294,130,929.91 to ¥962,310,557.00, reflecting a decrease of approximately 25.7%[16]. Strategic Initiatives - The company is in a transitional phase, actively responding to industry changes and focusing on retail business adjustments, which may require time to yield results[5]. - The company approved the establishment of Hefei Hejiaxing Supply Chain Technology Co., Ltd. in collaboration with its subsidiary, aiming to enhance supply chain efficiency[13]. - The company plans to publicly sell part of its idle properties to optimize resource allocation and improve asset operation efficiency[13]. - The company participated in the investment to establish the Hefei State-owned Assets Innovation Development Fund, indicating a strategic move towards innovation and development[13]. - The company aims to enhance market expansion strategies and explore potential mergers and acquisitions to drive future growth[19]. Investment Performance - The company reported an investment income of ¥13,324,696.66, significantly higher than ¥7,308,180.21 in the previous period, indicating improved investment performance[19]. - The net cash flow from investment activities was -59,947,265.58, an improvement from -299,824,870.56 in the previous period[22]. - Cash inflow from investment activities was 336,632,004.18, slightly up from 317,674,832.56, showing a growth of about 5.5%[22].

Financial Performance - The company's revenue for Q1 2025 was ¥39,559,469.07, representing an increase of 18.13% compared to ¥33,488,273.91 in the same period last year[3] - The net loss attributable to shareholders was ¥4,734,902.81, a 17.20% improvement from a loss of ¥5,718,744.88 in Q1 2024[3] - The company's net profit attributable to shareholders for the fiscal year 2024 is reported at -47.104 million RMB, leading to a risk warning for delisting[12] - Net profit for the current period was ¥-4,716,560.29, an improvement from ¥-6,165,410.48 in the previous period, indicating a reduction in losses[19] - The weighted average return on equity was -1.67%, slightly improved from -1.68% in the previous year[3] - The company reported a basic and diluted earnings per share of ¥-0.0176, an improvement from ¥-0.0213 in the previous period[20] Cash Flow and Liquidity - The net cash flow from operating activities increased by 6.73% to ¥1,591,984.52 from ¥1,491,573.82 year-on-year[3] - Cash inflow from operating activities totaled ¥48,411,558.82, up from ¥45,180,499.57, representing a growth of 5.1%[21] - The total cash increase for the period was CNY 7,671,010.09, compared to a decrease of CNY 90,008.72 in the previous period[22] - The cash and cash equivalents at the end of the period totaled CNY 28,324,321.39, a decrease from CNY 39,051,833.00 in the previous period[22] - The cash flow from operating activities totaled CNY 46,819,574.30, compared to CNY 43,688,925.75 in the previous period, indicating an increase of 4.9%[22] Assets and Liabilities - The total assets decreased by 3.29% to ¥386,602,875.24 from ¥399,764,672.35 at the end of the previous year[3] - The total assets of the company as of March 31, 2025, amount to 386.60 million RMB, a decrease from 399.76 million RMB at the beginning of the period[14] - Total liabilities decreased to ¥107,021,109.56 from ¥115,473,307.93, a reduction of 7.9%[16] - The total liabilities include short-term borrowings of 40 million RMB, unchanged from the previous period[15] - The company has a total of 155.24 million RMB in non-current assets, an increase from 146.77 million RMB[15] Investments and Expenses - Research and development expenses rose by 31.70% to ¥5,041,300.81, primarily due to increased investment in R&D materials[8] - Long-term equity investments increased by 100% to ¥10,405,119.00, reflecting an increase in external investments[6] - Research and development expenses rose to ¥5,041,300.81, compared to ¥3,827,893.10, marking a 31.7% increase[19] - Total operating costs increased to ¥42,047,960.51, up from ¥38,860,867.30, reflecting a rise of 5.4%[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 13,060[10] - The largest shareholder, Yu Rongqing, holds 32.52% of the shares, totaling 87,420,512 shares[10] Other Income and Comprehensive Income - The company reported a significant increase in other income, which rose by 361,454.65% to ¥191,407.03, mainly due to the write-off of payables[8] - Other comprehensive income after tax for the current period was ¥6,961.46, down from ¥149,369.75, indicating a significant decrease[20] Taxation - The company experienced a 50.51% increase in taxes and surcharges, amounting to ¥587,060.37, primarily due to increased VAT payable[6] Audit Status - The company has not yet audited the first quarter report for 2025[23]

珠海中富实业股份有限公司 2025 年第一季度报告 2025 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 证券代码：000659 证券简称：珠海中富 公告编号：2025-036 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 珠海中富实业股份有限公司 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 单位：元 3.第一季度报告是否经审计 □是 否 1 珠海中富实业股份有限公司 2025 年第一季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | | | | （%） | | 营业收入（元） | 238,115,171.94 | 235,820,275.72 | 0.97% | | 归属于上市 ...

东莞勤上光电股份有限公司 2025 年第一季度报告 证券代码：002638 证券简称：勤上股份 公告编号：2025-026 东莞勤上光电股份有限公司 2025 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经审计 □是 否 1 （二） 非经常性损益项目和金额 适用 □不适用 单位：元 | 项目 | 本报告期金额 | 说明 | | --- | --- | --- | | 非流动性资产处置损益（包括已计提资产减值准备的冲销 | 2,058.58 | | | 部分） | | | | 计入当期损益的政府补助（与公司正常经营业务密切相 关、符合国家政策规定、按照确定的标准享有、对公司损 | 101,964.37 | | | 益产生持续影响的政府补助除外） | ...

Revenue and Profitability - The company's revenue for Q1 2025 was CNY 337,017,694.93, representing a 6.94% increase compared to CNY 315,143,112.49 in the same period last year[4]. - Net profit attributable to shareholders increased by 11.67% to CNY 28,397,946.30 from CNY 25,431,095.91 year-on-year[4]. - The net profit after deducting non-recurring gains and losses rose by 28.63% to CNY 20,122,600.56, up from CNY 15,644,056.47 in the previous year[4]. - Basic and diluted earnings per share increased by 33.33% to CNY 0.04 from CNY 0.03 year-on-year[4]. - The company's net profit for the current period is CNY 29,200,290.43, an increase of 15.5% compared to CNY 25,353,942.97 in the previous period[16]. - The total profit amount is CNY 37,107,088.58, up from CNY 33,240,476.23, reflecting a growth of 11.3%[16]. - Operating income for the current period is CNY 37,225,769.83, compared to CNY 33,052,693.41, indicating an increase of 12.6%[16]. - The company’s total comprehensive income for the current period is CNY 29,200,290.43, compared to CNY 25,353,942.97, marking a growth of 15.5%[16]. Cash Flow and Operating Activities - The net cash flow from operating activities decreased by 52.13%, amounting to -CNY 75,976,180.31, compared to -CNY 49,942,197.01 in the same period last year[4]. - The cash flow from operating activities shows a net outflow of CNY -75,976,180.31, worsening from CNY -49,942,197.01 in the previous period[19]. - Cash flow from investment activities has a net inflow of CNY 15,013,739.05, recovering from a net outflow of CNY -2,224,554.90 previously[19]. - The total cash inflow from operating activities is CNY 349,114,873.43, compared to CNY 337,112,671.42 previously, showing an increase of 3.4%[19]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,780,951,376.56, a decrease of 0.77% from CNY 4,817,858,249.29 at the end of the previous year[4]. - Total current assets decreased slightly to ¥2,696,979,945.87 from ¥2,704,510,505.82, a decline of 0.3%[12]. - Total non-current assets decreased to ¥2,083,971,430.69 from ¥2,113,347,743.47, a reduction of 1.4%[13]. - Total liabilities decreased to ¥692,703,470.05 from ¥758,810,633.21, a decline of 8.7%[13]. - Cash and cash equivalents decreased to ¥708,140,179.27 from ¥772,831,729.64, a decrease of 8.4%[12]. Shareholders' Equity - Shareholders' equity attributable to shareholders increased by 0.71% to CNY 4,054,601,432.53 from CNY 4,026,203,486.23 at the end of the previous year[4]. - Total equity attributable to shareholders of the parent company increased to ¥4,054,601,432.53 from ¥4,026,203,486.23, an increase of 0.7%[14]. Investment and Expenses - Investment income grew by 50.86% year-on-year, primarily due to increased interest from large orders during the reporting period[7]. - Research and development expenses for the current period were ¥15,044,041.38, down 13.8% from ¥17,447,367.83 in the previous period[15]. - The company received CNY 640,000,000.00 from investment recoveries, up from CNY 500,000,000.00 in the previous period[19]. Accounts Receivable and Financing - Accounts receivable financing increased by 48.43% compared to the beginning of the period, attributed to an increase in 6+9 bank notes held[8]. - Accounts receivable increased to ¥479,875,888.03 from ¥386,693,259.55, reflecting a growth of 24.1%[12]. - The company reported a significant increase in construction in progress by 86.52% compared to the beginning of the period, due to increased equipment purchases[8].